tiprankstipranks
Trending News
More News >
Minerva Neurosciences (NERV)
NASDAQ:NERV

Minerva Neurosciences (NERV) Price & Analysis

Compare
572 Followers

NERV Stock Chart & Stats


Bulls Say, Bears Say

Bulls Say
Drug SafetyThe study demonstrated an acceptable safety profile of co-administration of the two medications, and no relevant PK interactions were observed between the two drugs.
Partnership And SupportBoehringer Ingelheim owns 18% of the company after taking a stake in Minerva in 2023, so it is suspected they will support the further development of roluperidone.
Bears Say
Financial PerformanceThe company reported cash at $21.5M by the end of 2024, compared with the cash position at $41M by the end of 2023; the company should have approximately one-year cash runway.
Regulatory ChallengesThe company's efforts to avoid needing to do another Phase 3 study appears to be counterproductive since the Agency has made it clear on the need for at least one additional study to support the safety and effectiveness of roluperidone.

Financials

Options Prices

Currently, No data available
---

Ownership Overview

6.80%21.21%0.29%68.12%
6.80%
Insiders
0.29% Other Institutional Investors
68.12% Public Companies and
Individual Investors

NERV FAQ

What was Minerva Neurosciences’s price range in the past 12 months?
Minerva Neurosciences lowest stock price was $1.15 and its highest was $3.50 in the past 12 months.
    What is Minerva Neurosciences’s market cap?
    Minerva Neurosciences’s market cap is $11.68M.
      When is Minerva Neurosciences’s upcoming earnings report date?
      Minerva Neurosciences’s upcoming earnings report date is Aug 12, 2025 which is in 40 days.
        How were Minerva Neurosciences’s earnings last quarter?
        Minerva Neurosciences released its earnings results on May 13, 2025. The company reported -$0.5 earnings per share for the quarter, beating the consensus estimate of -$1.07 by $0.57.
          Is Minerva Neurosciences overvalued?
          According to Wall Street analysts Minerva Neurosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Minerva Neurosciences pay dividends?
            Minerva Neurosciences does not currently pay dividends.
            What is Minerva Neurosciences’s EPS estimate?
            Minerva Neurosciences’s EPS estimate is -0.9.
              How many shares outstanding does Minerva Neurosciences have?
              Minerva Neurosciences has 6,993,406 shares outstanding.
                What happened to Minerva Neurosciences’s price movement after its last earnings report?
                Minerva Neurosciences reported an EPS of -$0.5 in its last earnings report, beating expectations of -$1.07. Following the earnings report the stock price went same 0%.
                  Which hedge fund is a major shareholder of Minerva Neurosciences?
                  Currently, no hedge funds are holding shares in NERV

                  Company Description

                  Minerva Neurosciences

                  Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company primarily focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is engaged in creating innovative therapies for patients suffering from neuropsychiatric disorders, including schizophrenia, depression, and Parkinson's disease, with its core product candidates being roluperidone and MIN-301.
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Traws Pharma
                  Athira Pharma
                  Addex Therapeutics
                  Sensei Biotherapeutics
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis